We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

By LabMedica International staff writers
Posted on 26 Aug 2014
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).
Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).

The evaluation of lymphoid proliferations in these specimens can be particularly problematic, given the frequent presence of coexisting inflammatory conditions and the manner in which these specimens are processed.

Laboratory scientists at the Hospital of the University of Pennsylvania (Philadelphia, PA, USA) searched for all serous effusions specimens such as pleural fluid, peritoneal fluid, and pericardial fluid, and CSF specimens in which flow cytometry was performed, during the time period June 2008 to July 2012. Six-color flow cytometry was performed according to the manufacturer's protocol on a FACSCanto II flow cytometer (BD Biosystems; San Jose, CA, USA). A panel using different antibodies from Becton Dickinson Immunocytometry Systems, (San Jose, CA, USA) was utilized.

Flow cytometry was performed in 184 of 6,925 total cases (2.7% of all fluids). Flow cytometry was performed in 4.8% of pleural fluids (positive findings in 38%, negative in 40%, and atypical in 18%), 1.1% of peritoneal fluids (positive in 40%, negative in 50%, and atypical in 10%), 1.9% of pericardial fluids (positive in 67%, negative in 33%), and 1.9% of CSFs (positive in 23%, negative in 55%, atypical in 3%).

The authors concluded that atypical flow cytometry findings and atypical morphologic findings in the context of negative flow cytometry results led to the definitive diagnosis of a lymphoproliferative disorder in a significant number of cases when repeat procedures and ancillary studies were performed. Flow cytometry is especially suited for cells in fluid specimens, where aggregates of cells and extracellular matrix elements that may interfere with obtaining single cells for analysis are less prominent than in solid tissue specimens. In addition, it is well known to increase the sensitivity of detecting neoplastic populations of cells over morphology alone. The study was published in the August 2014 issue of the journal Diagnostic Cytopathology.

Related Links:

Hospital of the University of Pennsylvania 
BD Biosystems
Becton Dickinson


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5

Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more